Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both episodic and chronic migraine. They have been thoroug...

Full description

Bibliographic Details

Published in:	Медицинский совет
Main Authors:	N. V. Vashchenko, A. M. Uzhakhov, M. V. Bogorodskaya, D. Z. Korobkova, Ju. E. Azimova, K. V. Skorobogatykh
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2022-01-01
Subjects:	migraine preventive therapy cgrp monoclonal antibodies erenumab
Online Access:	https://www.med-sovet.pro/jour/article/view/6608